




Searching News Database: Nektar Therapeutics
HSMN NewsFeed - 26 Jan 2022
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
HSMN NewsFeed - 5 Aug 2021
Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth
Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth
HSMN NewsFeed - 19 Jul 2021
Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
HSMN NewsFeed - 20 Apr 2020
MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations
MindMed Promotes Jeanne Bonelle to Executive Vice President, Technical Operations
HSMN NewsFeed - 8 May 2018
Pliant Therapeutics Appoints Hoyoung Huh as Chairman and Éric Lefebvre as Chief Medical Officer
Pliant Therapeutics Appoints Hoyoung Huh as Chairman and Éric Lefebvre as Chief Medical Officer
HSMN NewsFeed - 27 Dec 2016
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
Shire Announces FDA Approval of Adynovate(R) for use in Children and Surgical Settings
HSMN NewsFeed - 19 Mar 2015
Daiichi Sankyo Signs Agreement With AstraZeneca To Co-Commercialize MOVANTIK In The US
Daiichi Sankyo Signs Agreement With AstraZeneca To Co-Commercialize MOVANTIK In The US
HSMN NewsFeed - 9 Feb 2015
InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer
InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer
HSMN NewsFeed - 19 May 2014
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development & Chief Medical Officer
HSMN NewsFeed - 6 Mar 2012
CytomX Therapeutics Appoints Hoyoung Huh, M.D., Ph.D., Chairman of Board of Directors
CytomX Therapeutics Appoints Hoyoung Huh, M.D., Ph.D., Chairman of Board of Directors
HSMN NewsFeed - 25 Jul 2011
TARIS Appoints Christopher Searcy as the Company’s Chief Business Officer
TARIS Appoints Christopher Searcy as the Company’s Chief Business Officer
HSMN NewsFeed - 9 Jun 2009
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
HSMN NewsFeed - 31 Dec 2008
Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
HSMN NewsFeed - 3 Sep 2008
Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
HSMN NewsFeed - 2 Jul 2008
Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
HSMN NewsFeed - 22 May 2008
Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
HSMN NewsFeed - 27 Feb 2008
Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
HSMN NewsFeed - 14 Feb 2008
BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
HSMN NewsFeed - 12 Feb 2008
Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
HSMN NewsFeed - 7 Jan 2008
Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
Baxter Announces Recombinant Factor IX Development Program For Hemophilia B
HSMN NewsFeed - 20 Dec 2007
Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
HSMN NewsFeed - 18 Sep 2007
New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
HSMN NewsFeed - 7 Jul 2006
Nektar and University of Alabama in Huntsville Announce Agreement to Settle Litigation
Nektar and University of Alabama in Huntsville Announce Agreement to Settle Litigation
HSMN NewsFeed - 1 Mar 2006
Pfizer Completes Acquisition of Worldwide Rights to Exubera From sanofi-aventis
Pfizer Completes Acquisition of Worldwide Rights to Exubera From sanofi-aventis
HSMN NewsFeed - 26 Jan 2006
European Commission Approves Exubera(R) (Inhaled Human Insulin) for Treatment of Type 1 and Type 2 Diabetes
European Commission Approves Exubera(R) (Inhaled Human Insulin) for Treatment of Type 1 and Type 2 Diabetes
HSMN NewsFeed - 12 Jan 2006
Pfizer to Acquire the sanofi-aventis Worldwide Rights to Exubera(R) (Inhaled Human Insulin)
Pfizer to Acquire the sanofi-aventis Worldwide Rights to Exubera(R) (Inhaled Human Insulin)
Additional items found! 30

Members Archive contains
30 additional stories matching:
Nektar Therapeutics
(Password required)
Nektar Therapeutics
(Password required)